JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
Antibodies from patients who have recovered from SARS can be quickly found and used to treat others with a new method developed by Swiss and U.S. scientists, the researchers reported Monday. Subscribe ...
In this ongoing, randomized, phase 3 trial, sotrovimab (a SARS-CoV-2–targeted monoclonal antibody) or placebo was administered to outpatients within 5 days after the onset of Covid-19 symptoms. The ...
A new study has revealed that while SARS-CoV-2 can weaken part of the body's early immune response, it may also ...
JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results